World’s First One-Minute Hepatitis C Antibody Test Facilitates Quick Triage

By LabMedica International staff writers
Posted on 21 May 2024

Image: The INSTI HCV Antibody Test is the world’s first one minute test (Photo courtesy of bioLytical Laboratories)

Rapid and accurate testing is crucial in the fight against Hepatitis C. Having regular access to testing helps ensure the prompt identification of potential Hepatitis C infections and facilitates immediate linkage to care, thus helping to reduce further transmission. Now, the first one-minute Hepatitis C antibody test can prove to be an excellent tool in managing this disease.

The INSTI HCV Antibody Test from bioLytical Laboratories (Richmond, BC, Canada) is the world’s first one-minute test that detects antibodies to the Hepatitis C virus, which are substances released into the bloodstream upon infection. The test includes procedural control for IgG and IgM and can identify HCV genotypes 1 through 6, delivering results in as little as 60 seconds. It is both highly accurate and affordable, designed for ease of use. This fully portable system does not require any additional equipment, enabling healthcare providers to conduct tests in various settings, from clinical laboratories to remote testing locations.

By providing results in one minute or less, the INSTI HCV Antibody Test supports rapid triage and facilitates quick access to treatment. Its quick turnaround is ideal for integration into diverse healthcare workflows. The test is simple to administer via a simple finger prick and requires minimal training, making it adaptable to a variety of settings, including clinics and emergency environments. By eliminating the need for venepuncture, the INSTI HCV Antibody Test reduces delays in treatment and improves the connection to subsequent care and treatment, meeting a critical clinical need.

“Our INSTI HCV Antibody Test provides a rapid and reliable tool to identify hepatitis C cases quickly, helping healthcare professionals test high-risk populations and reduce transmission,” said Robert Mackie, bioLytical CEO.

Related Links:
bioLytical Laboratories